Advertisement
BMY vs MRK
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Merck & Co., Inc. (MRK) Stock Comparison
Key Takeaways
- Momentum favors MRK: MRK has delivered materially stronger relative performance over the past year, while BMY has gained more modestly.
- Valuation favors BMY: BMY trades at a far lower price-to-earnings (P/E) multiple and offers a higher dividend yield than MRK.
- Analyst consensus diverges: Wall Street ratings skew toward "Buy" for MRK and "Hold" for BMY.
- Growth portfolios are the shared story: Both companies are repositioning around newer franchises as blockbuster patent expirations loom.
- Tickeron AI Verdict: On trend consistency, momentum, and relative positioning, Tickeron's AI currently leans toward MRK.
- For deeper detail, explore BMY Major News, BMY Today's Price Move, MRK Major News, and MRK Today's Price Move.
- To see which strategies are resonating in today's market, explore Trending AI Robots.
Introduction
Bristol-Myers Squibb and Merck & Co. are two of the largest biopharmaceutical franchises in the world, both competing across oncology, immunology, and cardiometabolic medicine. Because they operate in the same sector, investors frequently weigh them against one another when evaluating relative performance and market positioning. This stock comparison is especially relevant for investors focused on the healthcare sector, dividend income, and long-term pipeline execution, as well as traders monitoring shifting momentum between large-cap names. Recent weeks have produced notable divergences in the two companies' earnings narratives and share-price trends, making a side-by-side review timely.
BMY Overview and Recent Performance
BMY, Bristol-Myers Squibb, is a global biopharmaceutical company with a portfolio spanning oncology, hematology, immunology, and cardiovascular treatments. In recent market activity, the stock has advanced from its 52-week low but remains well below its 52-week high, reflecting a more measured recovery. Recent earnings showed revenue growth in the low-single-digit percentage range, supported by the company's newer "Growth Portfolio" products, but profitability came under pressure as management trimmed earnings guidance and flagship product Opdivo sales disappointed expectations. The company also disclosed it halted a clinical program, which contributed to a cautious near-term tone. Several analysts lowered price targets in response, leaving consensus at "Hold." On the positive side, BMY offers an attractive dividend yield and trades at a relatively low earnings multiple, appealing to value-oriented and income-focused investors.
MRK Overview and Recent Performance
MRK, Merck & Co., is a diversified healthcare leader known for its oncology franchise, vaccines, and animal health division. In recent weeks, the stock has traded near its 52-week high after a strong run, supported by robust technical momentum and favorable analyst revisions. Recent results showed revenue growth in the mid-single-digit percentage range, driven by its oncology portfolio and steady animal health sales, although reported earnings per share (EPS) declined year over year, partly reflecting elevated acquisition-related charges. The company has continued advancing its pipeline, including new clinical trial initiations and regulatory developments. Analysts generally maintain a "Buy" consensus with price targets above the current share price. Key risks center on upcoming competition for its flagship oncology product and a premium valuation relative to earnings.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of covered securities. Because market conditions shift constantly, only a select group of the most suitable and best-performing bots earns a place in the curated Trending AI Robots section. This collection highlights strategies that are currently demonstrating strong relative strength and alignment with prevailing market dynamics, giving traders a data-driven starting point for evaluating automated approaches. Whether you focus on swing trading, momentum, or longer-horizon positioning, exploring these bots can help you identify tools matched to your objectives. Visit the Trending AI Robots page to review the latest top-performing strategies.
Head-to-Head Comparison
While both companies are large-cap pharmaceutical leaders, their current profiles differ sharply. MRK carries stronger recent price momentum and sits near multi-month highs, whereas BMY has experienced more volatile, two-way trading following mixed earnings. On valuation, BMY trades at a meaningfully lower P/E multiple and higher dividend yield, making it comparatively inexpensive; MRK commands a premium multiple that reflects its stronger growth trajectory but also introduces valuation risk. Growth drivers also differ: MRK benefits from a dominant oncology franchise and diversified animal health segment, while BMY leans on its Growth Portfolio as legacy products face pressure. Both face pipeline and patent-expiration risks, but sentiment currently favors MRK, which holds a "Buy" consensus versus BMY's "Hold" and has seen more positive analyst target revisions in recent weeks.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative performance, momentum, and analyst positioning, Tickeron's AI would currently lean toward MRK over BMY. MRK has demonstrated more sustained upward price structure, trades nearer its highs, and carries a more constructive consensus outlook, while BMY's mixed earnings narrative and cautious analyst revisions introduce greater near-term uncertainty. That said, BMY's lower valuation and higher yield remain meaningful counterweights, and the AI's view reflects a probabilistic assessment of current conditions rather than a definitive forecast. Traders and investors should weigh these dynamics against their own objectives and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and MRK is a Buy.
Aroon Indicator for BMY shows an upward move is likely
BMY's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator showed a similar pattern. In 147 of the 217 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 15 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 50 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 55%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 25 of 49 cases over the following month. The odds of a continued upward trend are 51%.
BMY moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +2.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 68 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly worse than average.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.421). P/E Ratio (13.627) is within average values for comparable stocks, (21.700). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
Aroon Indicator for MRK shows an upward move is likely
MRK's Aroon Indicator triggered a bullish signal on November 02, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 265 similar instances where the Aroon Indicator showed a similar pattern. In 174 of the 265 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MRK as a result. In 52 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 28 of 50 cases over the following month. The odds of a continued upward trend are 56%.
MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MRK crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
BMY | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 66 | 29 | |
SMR RATING 1..100 | 22 | 79 | |
PRICE GROWTH RATING 1..100 | 44 | 11 | |
P/E GROWTH RATING 1..100 | 63 | 1 | |
SEASONALITY SCORE 1..100 | 65 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (88) in the Pharmaceuticals Major industry is in the same range as BMY (96). This means that MRK’s stock grew similarly to BMY’s over the last 12 months.
MRK's Profit vs Risk Rating (29) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (66). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (79). This means that BMY’s stock grew somewhat faster than MRK’s over the last 12 months.
MRK's Price Growth Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (44). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
MRK's P/E Growth Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (63). This means that MRK’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | MRK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | N/A |
| Stochastic ODDS (%) | 2 days ago 51% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 55% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 51% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 56% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 57% |
| Advances ODDS (%) | 10 days ago 56% | 13 days ago 57% |
| Declines ODDS (%) | 6 days ago 55% | 6 days ago 51% |
| BollingerBands ODDS (%) | 2 days ago 52% | N/A |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while MRK’s FA Score has 3 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 7 TA indicator(s) are bullish while MRK’s TA Score has 7 bullish TA indicator(s).
- BMY’s TA Score: 7 bullish, 3 bearish.
- MRK’s TA Score: 7 bullish, 1 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +1.77% price change this week, while MRK (@Pharmaceuticals: Major) price change was +2.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.36%. For the same industry, the average monthly price growth was +2.43%, and the average quarterly price growth was +7.01%.
Reported Earning Dates
BMY is expected to report earnings on Feb 04, 2027.
MRK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-1.36% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.